Pearls and Pitfalls in the Therapeutic Use of Botulinum Toxin

Botulinum toxin is a potent toxin and powerful therapeutic tool. Botulinum toxin has therapeutic application in the treatment of a host of neurological, ophthalmologic, gastroenterological, urologic, and dermatologic conditions. Although there are issues specific to each disorder for which botulinum toxin therapy is employed, there are several common principles. This article reviews several of these general principles by addressing common questions that arise in the therapeutic use of botulinum toxin. Areas of focus include patient selection, drug preparation and delivery, use of electromyography to guide injections, drug resistance, and organization of a therapeutic botulinum toxin clinic.

KEYWORDS

Botulinum toxin - dystonia - therapy

REFERENCES

• 1 Greenfield R A, Brown B R, Hutchins J B et al.. Microbiological, biological, and chemical weapons of warfare and terrorism.  Am J Med Sci. 2002;  323 326-340
• 2 Aoki K. Pharmacology and immunology of botulinum toxin serotypes.  J Neurol. 2001;  248(suppl 1) 3-10
• 3 Hallett M. How does botulinum toxin work?.  Ann Neurol. 2000;  48 7-8
• 4 Byrnes M L, Thickbroom G W, Wilson S A et al.. The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection.  Brain. 1998;  121 977-988
• 5 Gilio F, Curra A, Lorenzano C et al.. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia.  Ann Neurol. 2000;  48 20-26
• 6 Saadia D, Voustianiouk A, Wang A K, Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study.  Neurology. 2001;  57 2095-2099
• 7 Heckmann M, Ceballos-Baumann A O, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating).  N Engl J Med. 2001;  344 488-493
• 8 Pal P K, Calne D B, Calne S, Tsui J K. Botulinum toxin A as treatment for drooling saliva in PD.  Neurology. 2000;  54 244-247
• 9 Mancini F, Zangaglia R, Cristina S et al.. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.  Mov Disord. 2003;  18 685-688
• 10 Voller B, Sycha T, Gustorff B et al.. A randomized double-blind placebo controlled study on analgesic effects of botulinum toxin A.  Neurology. 2003;  61 940-944
• 11 Kramer H H, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin.  J Neurol. 2003;  250 188-193
• 12 Aoki K. Evidence for antinociceptive activity of botulinum toxin type A in pain management.  Headache. 2003;  43 S9-S15
• 13 Welch M, Purkiss J, Foster K. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.  Toxicon. 2000;  38 245-258
• 14 Scott A. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.  Ophthalmology. 1980;  87 1044-1049
• 15 Tsui J K, Eisen A, Stoessl A J, Calne S, Calne D B. Double-blind study of botulinum toxin in spasmodic torticollis.  Lancet. 1986;  2 245-247
• 16 Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia.  Neurology. 1990;  40 277-280
• 17 Brin M F, Fahn S, Moskowitz C et al.. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.  Mov Disord. 1987;  2 237-254
• 18 Binder W J, Brin M F, Blitzer A, Schoenrock L D, Pogoda J M. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.  Otolaryngol Head Neck Surg. 2000;  123 669-676
• 19 Mathew N T, Kaup A O. The use of botulinum toxin type A in headache treatment.  Curr Treat Options Neurol. 2002;  4 365-373
• 20 Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of tension-type headache.  Curr Rev Pain. 2000;  4 31-35
• 21 Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.  Headache. 2000;  40 445-450
• 22 Brin M, Swope D, O'Brian C, Abbasi S, Pogoda J. Botox for migraine: double-blind, placebo controlled region specific evaluation.  Cephalgia. 2000;  20 421-422
• 23 Troost B. Botulinum toxin type A (Botox) therapy for intractable headache.  Headache. 2002;  42 449-450
• 24 Blumenfeld A. Decrease in headache medication use and cost after botulinum toxin type A (Botox) treatment in a high triptan use population.  Headache. 2002;  42 409
• 25 Gobel H, Heinze A, Heinze-Kuhn K, Jost W. Evidence-based medicine: botulinum toxin A in migraine and tension-type headache.  J Neurol. 2001;  248(suppl 1) 34-38
• 26 Brin M F, Lyons K E, Doucette J et al.. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.  Neurology. 2001;  56(11) 1523-1528
• 27 Guyer B. Some unresolved issues with botulinum toxin.  J Neurol. 2001;  248(suppl 1) 11-13
• 28 Greene P. Potency of frozen/thawed botulinum toxin type A in the treatment of torsion dystonia.  Otolaryngol Head Neck Surg. 1993;  109 968-969
• 29 Setler P. The biochemistry of botulinum toxin type B.  Neurology. 2000;  55 S22-S28
• 30 Barbano R L. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful.  Muscle Nerve. 2001;  24(11) 1567-1568
• 31 Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required.  Muscle Nerve. 2001;  24(11) 1568-1570
• 32 Van Gerpen J A, Matsumoto J Y, Ahlskog J E, Maraganore D M, McManis P G. Utility of an EMG mapping study in treating cervical dystonia.  Muscle Nerve. 2000;  23(11) 1752-1756
• 33 Brans J W, de Boer I P, Aramideh M, Ongerboer de Visser B W, Speelman J D. Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance.  J Neurol. 1995;  242(8) 529-534
• 34 Dubinsky R M, Gray C S, Vetere-Overfield B, Koller W C. Electromyographic guidance of botulinum toxin treatment in cervical dystonia.  Clin Neuropharmacol. 1991;  14(3) 262-267
• 35 Comella C L, Buchman A S, Tanner C M, Brown-Toms N C, Goetz C G. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance.  Neurology. 1992;  42(4) 878-882
• 36 Molloy F M, Shill H A, Kaelin-Lang A, Karp B I. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia.  Neurology. 2002;  58(5) 805-807
• 37 Hughes R, Whaler B C. Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin.  J Physiol. 1962;  160 221-233
• 38 Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans.  Mov Disord. 1997;  12(1) 89-94
• 39 Chen R, Karp B I, Goldstein S R et al.. Effect of muscle activity immediately after botulinum toxin injection for writer's cramp.  Mov Disord. 1999;  14 307-312
• 40 Hesse S, Reiter F, Konrad M, Jahnke M T. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial.  Clin Rehabil. 1998;  12(5) 381-388
• 41 Ross M H, Charness M E, Sudarsky L, Logigian E L. Treatment of occupational cramp with botulinum toxin: diffusion of toxin to adjacent noninjected muscles.  Muscle Nerve. 1997;  20(5) 593-598
• 42 Borodic G E, Ferrante R, Pearce L B, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections.  Mov Disord. 1994;  9(1) 31-39
• 43 Tarsy D. Comparison of acute- and delayed-onset posttraumatic cervical dystonia.  Mov Disord. 1998;  13(3) 481-485
• 44 Truong D D, Dubinsky R, Hermanowicz N et al.. Posttraumatic torticollis.  Arch Neurol. 1991;  48(2) 221-223
• 45 Hsiung G Y, Das S K, Ranawaya R, Lafontaine A L, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.  Mov Disord. 2002;  17(6) 1288-1293
• 46 Kessler K R, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.  J Neurol. 1999;  246(4) 265-274
• 47 Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis.  Mov Disord. 1994;  9(2) 213-217
• 48 Jankovic J, Vuong K D, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.  Neurology. 2003;  60(7) 1186-1188
• 49 Turkel C, Dru R, Daggett S, Brin M. Neutralizing antibody formation is rare following repeated injections of a low-protein formulation of botulinum toxin type A (BTX-A) in patients with post-stroke spasticity.  Neurology. 2002;  58(suppl 7) A316
• 50 Hanna P A, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies.  J Neurol Neurosurg Psychiatry. 1999;  66 612-616
• 51 Hanna P A, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response.  Neurology. 1998;  50(6) 1624-1629
• 52 Gordon P H, Gooch C L, Greene P E. Extensor digitorum brevis test and resistance to botulinum toxin type A.  Muscle Nerve. 2002;  26(6) 828-831
• 53 Birklein F, Walther D, Bigalke H, Winterholler M, Erbguth F. Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies.  Ann Neurol. 2002;  52(1) 68-73
• 54 Birklein F, Erbguth F. Sudomotor testing discriminates between subjects with and without antibodies against botulinum toxin A: a preliminary observation.  Mov Disord. 2000;  15(1) 146-149
• 55 Gelb D J, Yoshimura D M, Olney R K, Lowenstein D H, Aminoff M J. Change in pattern of muscle activity following botulinum toxin injections for torticollis.  Ann Neurol. 1991;  29(4) 370-376
• 56 Brin M F, Lew M F, Adler C H et al.. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.  Neurology. 1999;  53(7) 1431-1438
• 57 Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.  J Neurol. 2003;  250(8) 967-969
• 58 Naumann M, Toyka K V, Mansouri Taleghani B et al.. Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin.  J Neurol Neurosurg Psychiatry. 1998;  65(6) 924-927
• 59 Munchau A, Palmer J D, Dressler D et al.. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia.  Brain. 2001;  124 769-783
• 60 Kupsch A, Kuehn A, Klaffke S et al.. Deep brain stimulation in dystonia.  J Neurol. 2003;  250(suppl 1) I47-I52